Evonik Industries AG Earnings Recaps
Q3 2025
Nov 4, 2025
Evonik Industries experienced a challenging Q3 2025, prompting a reduction in full-year EBITDA guidance to EUR 1.9 billion, despite expectations for improved performance in Q4 due to sales recoveries in key segments.
Key takeaways
- Q3 EBITDA was notably weaker, primarily due to cautious customer behavior and ongoing market headwinds.
- The company anticipates a recovery in Q4, driven by a year-end sales surge in the Health Care segment and increased capacity in Animal Nutrition.
- Free cash flow showed positive progress, with approximately EUR 300 million generated in Q3, bolstering confidence in achieving cash conversion guidance of 30% to 40%.
- Significant workforce reductions of over 740 employees were implemented, aimed at streamlining operations and supporting long-term strategy amidst a tough market landscape.